Current State of Immunotherapy for Treatment of Glioblastoma

At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several fail...

Descripción completa

Detalles Bibliográficos
Autores principales: McGranahan, Tresa, Therkelsen, Kate Elizabeth, Ahmad, Sarah, Nagpal, Seema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Neuro-oncology (GJ Lesser, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394457/
https://www.ncbi.nlm.nih.gov/pubmed/30790064
http://dx.doi.org/10.1007/s11864-019-0619-4
_version_ 1783398898842206208
author McGranahan, Tresa
Therkelsen, Kate Elizabeth
Ahmad, Sarah
Nagpal, Seema
author_facet McGranahan, Tresa
Therkelsen, Kate Elizabeth
Ahmad, Sarah
Nagpal, Seema
author_sort McGranahan, Tresa
collection PubMed
description At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM appears most hopeful for combination of immune therapies to overcome the profound immunosuppression of this disease. Understanding biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM
format Online
Article
Text
id pubmed-6394457
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-63944572019-03-15 Current State of Immunotherapy for Treatment of Glioblastoma McGranahan, Tresa Therkelsen, Kate Elizabeth Ahmad, Sarah Nagpal, Seema Curr Treat Options Oncol Neuro-oncology (GJ Lesser, Section Editor) At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM appears most hopeful for combination of immune therapies to overcome the profound immunosuppression of this disease. Understanding biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM Springer US 2019-02-21 2019 /pmc/articles/PMC6394457/ /pubmed/30790064 http://dx.doi.org/10.1007/s11864-019-0619-4 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Neuro-oncology (GJ Lesser, Section Editor)
McGranahan, Tresa
Therkelsen, Kate Elizabeth
Ahmad, Sarah
Nagpal, Seema
Current State of Immunotherapy for Treatment of Glioblastoma
title Current State of Immunotherapy for Treatment of Glioblastoma
title_full Current State of Immunotherapy for Treatment of Glioblastoma
title_fullStr Current State of Immunotherapy for Treatment of Glioblastoma
title_full_unstemmed Current State of Immunotherapy for Treatment of Glioblastoma
title_short Current State of Immunotherapy for Treatment of Glioblastoma
title_sort current state of immunotherapy for treatment of glioblastoma
topic Neuro-oncology (GJ Lesser, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394457/
https://www.ncbi.nlm.nih.gov/pubmed/30790064
http://dx.doi.org/10.1007/s11864-019-0619-4
work_keys_str_mv AT mcgranahantresa currentstateofimmunotherapyfortreatmentofglioblastoma
AT therkelsenkateelizabeth currentstateofimmunotherapyfortreatmentofglioblastoma
AT ahmadsarah currentstateofimmunotherapyfortreatmentofglioblastoma
AT nagpalseema currentstateofimmunotherapyfortreatmentofglioblastoma

Ejemplares similares